Abstract: There is provided a display unit that achieves more favorable image. This display unit includes: an illumination unit including a light-guiding plate; and a display section adhered to the light-guiding plate to face the light-guiding plate, and performing image display by utilizing light from the light-guiding plate. The light-guiding plate has first and second internal reflection surfaces facing each other. At least one of the first and second internal reflection surfaces is provided with a plurality of scattering regions that scatter first illumination light from outside and allow scattered light travelling from the first internal reflection surface towards the display section to be emitted.

Abstract: A coil device, which has a coil composed of a core and a winding on the core, and a terminal having a base seat for holding the coil and terminal elements. The coil device has a flange on one side of the core with no flange being provided on the other side of the core. This allows molding by using a mold and can reduce a thickness of the flange of the core and thereby realize a reduction in the thickness of the coil device.

Abstract: There is disclosed a coil device, which has a coil composed of a core and a winding on the core, and a terminal having a base seat for holding the coil and terminal elements. The coil device has a flange on one side of the core with no flange being provided on the other side of the core. This allows molding by using a mold and can reduce a thickness of the flange of the core and realize reduction of thickness of the coil device.

Abstract: Disclosed is a color-selection mechanism with an aperture-grill type, color-selection electrode which includes tapes and slits that are disposed between the tapes. In this mechanism, when the arranged pitch of the slits is in the range of 0.310 to 0.221 mm, the width of the flat portion on the panel side of each tape of the color selection electrode is set to be 0.215 to 0.050 times the slit pitch, which is narrower than that in the related art, and when the arranged pitch of the slits is in the range of 0.220 to 0.100 mm, the width of the flat portion on the panel side of each tape of the color selection electrode is set to be 0.225 to 0.050 times the slit pitch, which is narrower than that in the related art. With this configuration, the amount of reflection of an electron beam that has been reflected from the inner surface of the panel from the flat portion on the panel side of each tape to an undesired phosphor can be reduced. As a result, the degradation of color purity in a CRT can be reduced.

Abstract: A cathode-ray tube consuppress deterioration and reduce unevenness in color of a picture by preventing an electrode element thereof from being twisted. The color cathode-ray tube includes a frame and an aperture grill stretched across and fixed on the frame and having an electrode element. The aperture grill is stretched across and fixed on the frame in a state that the frame is applied with a compressive force and the aperture grill is applied with a tension. In a process of stretching and fixing the aperture grill across and on the frame, of the tension applied to the aperture grill, a maximum tension applied to the electrode element is set within the range from 30% to 85% of a tensile strength of the electrode element.

Abstract: Disclosed is a shadow-mask type color cathode-ray tube comprising a faceplate having a curved inner surface which prevents degrouping and a substantially flat outer surface. In this color cathode-ray tube, the resolution is not deteriorated in the peripheral portion and an inespensive flat material is usable as a glass plate provided with a reflection reducing coating or a touch panel attached to the outer surface of the faceplate. Since a shadow mask supported with a tension applied thereto is usable, the positional deviation of the apertures due to the expansion of the shadow mask during operation is prevented.

Abstract: 4-Imidazoline derivatives represented by the formula (I) and/or formula (II): ##STR1## wherein R.sup.1 represents C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or optionally substituted aralkyl; R.sup.2 and R.sup.3 independently represent hydrogen, C.sub.3 -C.sub.20 alkyl, C.sub.3 -C.sub.20 alkenyl, C.sub.3 -C.sub.20 alkynyl, C.sub.3 -C.sub.20 alkoxy, C.sub.3 -C.sub.20 alkenyloxy, C.sub.3 -C.sub.20 alkynyloxy, C.sub.3 -C.sub.8 cyloalkyl, C.sub.1 -C.sub.10 alkylthio, or optionally substituted aralkyl or aralkyloxy; R.sup.4 represents C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, or optionally substituted aralkyl; provided that R.sup.2 and R.sup.3 cannot be hydrogen at the same time, and pharmaceutically acceptable salts thereof. A pharmaceutical formulation containing the compound is also provided.

Abstract: Disclosed is a pharmaceutical having circulation ameliorating effect and antiulcer effect containing a prostaglandin I.sub.2 analogue represented by the formula shown below or a non-toxic salt of its salt or a cyclodextrin inclusion compound thereof as the effective ingredient: ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group having 1 to 12 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms or a phenyl group; A represents a pentyl group, a cyclopentyl group, a cyclohexyl group, a 1-methyl-3-hexynyl group, a 2-methyl-3-hexynyl group, a 1-methylhexyl group, a 2-phenethyl group, a 1,1-dimethylpentyl group, a 2-methylpentyl group, a 1-cyclohexylethyl group, a 2-methylhexyl group, a 1-methyl-3-pentynyl group or 1 2,6-dimethyl-5-heptenyl group; the double bond between the carbon atoms at 4- and 5-positions is E or Z or a mixture thereof, the asymmetric center in the substituent represented by A is R-configuration or S-configuration or a mixture thereof.

Abstract: According to the present invention, there are provided novel carboxystyrene derivatives of the general formula (I): wherein the symbols are as defined hereinabove. Also provided herein are leukotriene antagonists and phospholipase inhibitors containing the carboxystyrene derivative or pharmaceutically acceptable salt thereof as an effective ingredient.

Abstract: This invention relates to a novel prostacyclin represented by the formula: ##STR1## [wherein R.sup.1 represents --CO.sub.2 R.sup.5 group or --CONR.sup.6 R.sup.7 group; A is(i) --CH.dbd.CH--CH.sub.2 CH.sub.2 -- or(ii) --CH.sub.2 CH.sub.2 --O--CH.sub.2 --;B represents --C.tbd.C-- group; R.sup.2 represents an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, a phenyl group or a phenoxy group;R.sup.3 represents a hydrogen atom, a methyl group or a vinyl group; R.sup.4 represents a hydrogen atom, an acyl group, a tri(1 to 7 carbon atoms)hydrocarbyl-silyl group or a group forming an acetal bond with an oxygen atom of a hydroxy group; a double bond in the substituent represented by A is E or Z, or a mixture thereof; asymmetric center in the substituent represented by R.sup.

Abstract: There are disclosed a (2-chloro-3-oxo-1-alkenyl)-bicyclo[3.3.0 octene derivative represented by the formula: ##STR1## wherein R.sup.1 represents --CH.sub.2 CH.sub.2 CH.sub.2 COOR.sup.5, --CH.sub.2 CH.sub.2 --O--CH.sub.2 COOR.sup.5, --CH.dbd.CHCH.sub.2 COOR.sup.5 or --CH.sub.2 CH.sub.2 C.tbd.C--COOR.sup.5 group where R.sup.5 in the groups represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R.sup.2 represents a hydrogen atom, an acyl group having 1 to 7 carbon atoms, a tri(1 to 7 carbon atoms)-hydrocarbylsilyl group or a group forming an acetal bonding with an oxygen atom of a hydroxy group; R.sup.

Abstract: Disclosed are an aminostyryl compound represented by Formula I: ##STR1## wherein A represents a linking group having 3 to 4 chain members; B represents an unsubstituted or substituted 5 to 6-membered monocyclic type heterocyclic residue containing 1 to 2 hetero atoms, an unsubstituted or substituted condensed heterocyclic residue which contains 5 to 6-membered monocyclic type heterocycle containing 1 to 2 hetero atoms, a naphthyl group or an alkyl group having 5 to 7 carbon atoms,a composition having leukotriene antagonism which contains an aminostyryl compound represented by Formula I as the effective ingredient, and a method of antagonizing SRS based on leukotriene antagonistic activity by employing the same.

Abstract: Disclosed is a pharmaceutical composition having circulation ameliorating effect and antiulcer effect containing a prostaglandin I.sub.2 analogue represented by the formula shown below or a non-toxic salt or a cyclodextrin inclusion compound thereof as the effective ingredient: ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group having 1 to 12 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms or a phenyl group, A represents a pentyl group, a cyclopentyl group, a cyclohexyl group, a 1-methyl-3-hexynyl group, a 2-methyl-3-hexynyl group, a 1-methylhexyl group, a 2-phenethyl group, a 1,1-dimethylpentyl group, a 2-methylpentyl group, a 1-cyclohexylethyl group, a 2-methylhexyl group, a 1-methyl-3-pentynyl group or a 2,6-dimethyl-5-heptenyl group; the double bond between the carbon atoms at 4- and 5-positions is E or Z or a mixture thereof; the asymmetric center in the substituent represented by A is in the R-configuration or the S-configuration or a mixture thereof.